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to 0.990, p < 0.05). This was accompanied by an increase in 
neutrophil elastase expression by α-SMA-positive cells in 
the vessel wall. Small and medium-sized arteries exhibited 
significant CAA-independent α-SMA loss starting between 
Braak stage I and II–III, along with accumulation of phos-
phorylated paired helical filament (PHF) tau in the perivas-
cular space of intraparenchymal vessels. α-SMA remained 
at the decreased level throughout the later Braak stages. In 
contrast, arterioles exhibited significant α-SMA loss only 
at Braak stage V and VI/in AD subjects, which was CAA-
dependent/correlated with CAA burden (ρ = −0.422, 95 % 
CI −0.557 to −0.265, p < 0.0001). Collagen content was 
only significantly changed in small arteries. Our data indi-
cate that vessel wall remodelling of leptomeningeal arteries 
is an early-onset, Braak tau pathology-dependent process 
unrelated to CAA and AD, which potentially may contrib-
ute to downstream CAA-dependent microvascular pathol-
ogy in AD.
Keywords Hyperphosphorylated tau · Collagen · Internal 
elastic lamina · Neutrophil elastase · Vascular smooth 
muscle · Cerebrovascular pathology
Introduction
Pathologic cerebrovascular alterations are prominent in 
Alzheimer’s disease (AD) and include smooth muscle loss, 
vasculitis, cerebral amyloid angiopathy (CAA) with or 
without microhaemorrhaging, blood–brain barrier (BBB) 
leakage, altered vessel wall collagen content, and altera-
tions affecting neurovascular coupling [16, 17, 25, 39, 
40]. They contribute to the genesis of the neuron-hostile 
environment characteristic in AD. The question remains 
whether these vascular alterations are merely AD-related 
Abstract Alzheimer’s disease (AD) is characterised 
by pathologic cerebrovascular remodelling. Whether this 
occurs already before disease onset, as may be indicated by 
early Braak tau-related cerebral hypoperfusion and blood–
brain barrier (BBB) impairment found in previous studies, 
remains unknown. Therefore, we systematically quantified 
Braak tau stage- and cerebral amyloid angiopathy (CAA)-
dependent alterations in the alpha-smooth muscle actin 
(α-SMA), collagen, and elastin content of leptomeningeal 
arterioles, small arteries, and medium-sized arteries sur-
rounding the gyrus frontalis medialis (GFM) and hip-
pocampus (HIPP), including the sulci, of 17 clinically and 
pathologically diagnosed AD subjects (Braak stage IV–VI) 
and 28 non-demented control subjects (Braak stage I–IV). 
GFM and HIPP paraffin sections were stained for general 
collagen and elastin with the Verhoeff–van Gieson stain; 
α-SMA and CAA/amyloid β (Aβ) were detected using 
immunohistochemistry. Significant arterial elastin degrada-
tion was observed from Braak stage III onward and corre-
lated with Braak tau pathology (ρ = 0.909, 95 % CI 0.370 
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or have other, earlier origins. For example, vessel wall 
pathology is observed in normal ageing [25, 26] and may 
also play a role in primary age-related tauopathy (PART) 
[13, 61]. In the latter, hyperphosphorylation of tau protein 
causing neurofibrillary tangle (NFT) pathology occurs in 
the absence of amyloid β (Aβ) accumulation [13]. NFTs 
are also present at the earliest neurodegenerative stages 
that may progress to incipient AD or fully developed AD 
with or without concomitant Aβ pathology [8], which is 
interpreted by some that PART could be a mere pre-AD 
stage rather than a separate neurodegenerative disorder 
[15]. Clear is, though, that Braak tau pathology—whether 
as PART, related to AD, or underlying both—is accom-
panied by decreased cerebral blood flow [3, 9, 41]. Fur-
ther, decreased cerebral blood flow [22, 32, 36, 50] along 
with increased vascular resistance and impaired cerebral 
oxygen uptake [23, 36] and overall arterial stiffness [52] 
is observed in subjects with mild cognitive impairment, 
suggesting the existence of early vessel wall remodelling 
because changes in the vessel wall anatomy can affect 
blood flow. Arterial wall remodelling is of special inter-
est herein since an important aspect of especially large 
and medium-sized muscular arteries, besides functioning 
as a conduit, is to cushion the cardiac pulsatile blood flow 
waves to such extent that the pulsations experienced by the 
relatively fragile arteriolar and capillary wall are largely 
proportional to the wall’s distension capacities. This pre-
vents microvascular wall damage [44]. Furthermore, the 
cerebral arterial wall is instrumental in adequate function-
ing of perivascular drainage, one of the main cerebral clear-
ance routes [60, 62]. Collagen, elastin, and vascular smooth 
muscle form the arterial wall triad that contributes to the 
regulation of these blood flow dynamics, with arterial elas-
tin playing an important role in arterial wall recoil, affect-
ing shape during and after vascular smooth muscle-medi-
ated vessel constriction and dilatation.
Ageing negatively affects arterial elastin, thereby alter-
ing perfusion patterns [19, 64]. To our knowledge, it is not 
known whether Braak tau and/or AD pathology affects elas-
tin in cerebral arteries, similar to the finding that perivascu-
lar tau accumulation as observed in sporadic AD subjects 
and in a mouse model of tauopathy can instigate pathologic 
vessel wall changes [5, 48, 57]. Furthermore, although pre-
vious studies have shown CAA-dependent alpha-smooth 
muscle actin (α-SMA) and collagen loss in cerebral arteri-
oles of AD subjects [54, 55], quantitative analyses of such 
vessel wall remodelling in cerebral arteries according to 
Braak tau stage (called “Braak stage” henceforth) in paral-
lel to analysis of the arterioles in the same subjects have, 
to our knowledge, not been extensively performed. There-
fore, we systematically quantified Braak stage- and CAA-
dependent and -independent changes in collagen, elastin, 
and α-SMA and luminal diameters of the leptomeningeal 
arterioles, small arteries, and medium-sized arteries sur-
rounding the gyrus frontalis medialis (GFM) and hip-
pocampus (HIPP), including the sulci, of non-demented 
control (NDCTRL) and AD subjects. Concomitantly, we 
investigated the potential role of neutrophil elastase in 
affecting elastin integrity, and perivascular tau accumula-
tion in affecting the α-SMA content of the arterial wall at 
the different Braak stages. The three lead questions of this 
study are whether (1) remodelling of the vessel wall occurs 
already at early Braak stages, (2) the type of remodelling is 
distinct between the arterioles and arteries, and (3) the type 
of remodelling is Braak stage and/or CAA dependent.
Materials and methods
Subjects and brain material
Paraffin-embedded GFM and HIPP tissue blocks of 45 sub-
jects with Braak stage pathology ranging from score I–VI 
and who were clinically and pathologically diagnosed as 
NDCTRL or AD subjects between 1998 and 2009 were 
obtained from the Netherlands Brain Bank (NBB), Neth-
erlands Institute for Neuroscience, Amsterdam. All brain 
material was collected from external/non-NBB-affiliated 
donors for or from whom the NBB had obtained a writ-
ten informed consent for a brain autopsy and the use of the 
material and clinical information for research purposes. 
The authors did not participate in the clinical and neuro-
pathological evaluations and diagnoses of the subjects. For 
each subject, the NBB provided the authors with informa-
tion on the antemortem cognitive status [AD (n = 17) or 
NDCTRL (n = 28)] as diagnosed clinically according to 
the clinical criteria of probable AD [14, 38]—the infor-
mation thereof was provided to the NBB by the respective 
external neurologist(s)—and post mortem on the Braak tau 
stage and amyloid β (Aβ) score according to [6, 7], based 
on Bodian, methenamine silver, and Congo red staining 
performed by the NBB. The neuropathological reports 
contained information about both the macro- and micro-
scopic evaluation of the brain of each subject, including 
the absence or presence of atrophy, specific discoloura-
tion, haemorrhages, and ventricular dilatation (macroscopic 
evaluation); and the presence or absence of senile and/or 
diffuse plaques, congophilic angiopathy, and neurofibril-
lary tangles (microscopic evaluation). The subjects’ demo-
graphics, neuropathological diagnoses, and clinical details 
are summarised in Table 1.
Histology
All reagents listed were purchased from Sigma-Aldrich 
(Basel, Switzerland) unless otherwise specified. The 
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HIPP and GFM tissue blocks obtained from the NBB 
were cut into 5-µm-thick sections and were mounted on 
SuperFrost® Plus microscope slides (VWR, Dietikon, 
Switzerland). Detailed histological staining procedures 
can be found in the Supplementary Materials and Meth-
ods. Briefly, following standard deparaffinisation and 
rehydration steps, sections for immunohistochemical 
staining were treated with antigen retrieval buffer fol-
lowed by co-incubation with primary goat anti-α-SMA 
antibody (ab21027; Abcam, Cambridge, UK) and pri-
mary mouse anti-Aβ (6E10, purified; Lucerna-Chem, 
Luzern, Switzerland) for 1 h at room temperature (RT). 
Subsequently, the sections were co-incubated with donkey 
anti-mouse-Alexa488 and donkey anti-goat-Cy3 anti-
body (both from Jackson ImmunoResearch, Suffolk, 
UK). HIPP and GFM sections adjacent to the ones immu-
nostained for α-SMA and Aβ were stained for collagen 
and elastin using the Verhoeff–van Gieson (VVG) stain. 
Another series of adjacent HIPP and GFM sections was 
stained for neutrophil elastase (primary rabbit anti-neu-
trophil elastase antibody, ab21595; Abcam, Cambridge, 
UK) using the VectaStain® Elite staining kit (Reacto-
Lab, Servion, Switzerland) in combination with the Vec-
tor® SG substrate per the manufacturer’s instructions. To 
compare collagen stained by the Van Gieson stain with 
collagen stained with a collagen IV-specific antibody, a 
Table 1  Demographics, neuropathological diagnoses, and clinical history of the subjects analysed
AD Alzheimer’s disease, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, COPD chronic obstructive pulmonary disease, 
CVA cerebrovascular accident, DM2 diabetes mellitus type 2, N/A not available, NDCTRL non-demented control
a The number in brackets represents the number of subjects with the respective ApoE isoform
b CERAD score. The number in brackets represents the number of subjects with the respective CERAD score
c Only vascular diseases and diseases affecting the vasculature are indicated
d The types of medication used were similar in all Braak stage groups—except for the use of antipsychotics in the Braak stage V and VI 
group—and included: angiotensin-converting-enzyme (ACE) inhibitors, loop diuretics, L-type Ca2+ channel blockers, sulfonylurea potassium 
channel blockers, heparin, non-steroidal anti-inflammatory drugs (NSAIDs; mainly acetaminophen, ibuprofen, and diclofenac), salicylates 
(mainly acetylsalicylic acid), opiates, benzodiazepines (mainly temazepam, oxazepam, and lorazepam), HMG-CoA reductase inhibitors/statins, 
β2-adrenergic receptor agonists, glucocorticoids, antibiotics, diarrhoea treatment (µ-opioid receptor agonists), peripheral dopamine D2/D3 
receptor antagonists (domperidone), proton pump inhibitors, digoxin, nitroglycerine, racetams, typical antipsychotics (pipamperone and halop-
eridol)
e Summary of the causes of death
f The number in brackets represents the number of subjects with the respective diagnosis. The three NDCTRL subjects were diagnosed as NDC-
TRLs on the basis of their clinical cognitive status
Braak stage ♂/♀
(n)
Age at death (mean ± SD, 
years)
ApoEa Amyloidb Diagnosis Historyc,d Cause of deathe
I 4/6 82.1 ± 9.6 0 (4)
3/2 (2)
3/3 (4)
O (6)
A (4)
NDCTRL Angina pectoris, COPD, 
CVA, DM2, hyperten-
sion
Acute myocardial infarc-
tion, cachexia, dehydra-
tion, pneumonia, sepsis
II 2/4 81.4 ± 5.7 N/A (2)
3/3 (3)
4/3 (1)
A (3)
B (1)
C (2)
NDCTRL Cardiac decompensation, 
COPD, DM2, emphy-
sema, hypertension
Cachexia, cardiac arrest, 
CVA (medium-sized), 
dehydration
III 4/5 84.0 ± 7.5 N/A (3)
0 (2)
3/2 (1)
3/3 (2)
4/3 (1)
A (2)
B (4)
C (3)
NDCTRL Angina pectoris, atrial 
fibrillation, cardiac 
decompensation, hyper-
tension
Cardiac arrest, CVA, sudden 
death
IV 3/5 91.2 ± 4.4 0 (1)
3/2 (2)
3/3 (2)
4/3 (3)
C (8) NDCTRL (3)f
AD (5)f
Cardiac decompensation, 
DM2, hypertension, 
pneumonia
Cachexia, cardiac arrest, 
dehydration, uncontrolled 
anti-coagulation therapy
V 2/3 89.0 ± 3.1 3/2 (1)
3/3 (3)
4/3 (1)
C (5) AD Atrial fibrillation, cardiac 
decompensation, 
hypercholesterolaemia, 
hypertension
Cardiac arrest, dehydration, 
pneumonia
VI 2/5 89.2 ± 3.4 3/3 (1)
4/3 (3)
4/4 (3)
C (7) AD Angina pectoris, CVA, 
hypertension, myocar-
dial infarction, vascular 
dementia (1 subject)
Acute myocardial infarc-
tion, cachexia, dehydra-
tion, pneumonia
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subset of sections was incubated with a mouse monoclo-
nal antibody against human collagen IV (M 0785; DAKO, 
Gløstrup, Denmark) followed by staining with a donkey 
anti-mouse-Cy5 antibody (Jackson ImmunoResearch, 
Suffolk, UK). Accumulation of phosphorylated paired 
helical filament tau (PHF-tau) in the perivascular space of 
intraparenchymal vessels was detected with an antibody 
against phosphorylated tau (mouse anti-phospho-PHF-tau 
(AT8), MN1020; ThermoFisher Scientific, Reinach, Swit-
zerland) followed by staining with a donkey anti-mouse-
Cy3 antibody (Jackson ImmunoResearch, Suffolk, UK).
Image acquisition
Detailed image acquisition procedures can be found in 
the Supplementary Materials and Methods. Microscopic 
images were acquired from leptomeningeal arterioles, 
small arteries, and medium-sized arteries surrounding the 
GFM and HIPP, including the sulci. Images of 10 to 15 
vessels of each vessel type/brain region/subject from the 
VVG and immunostained HIPP and GFM sections were 
acquired. Differentiation between the three vessel types 
was made according to vessel diameter, ranging from 50 
a
Score 0: no 
elasn degradaon
b
c
Arteriole Small artery Medium-sized artery Vein
Score 1: mild 
elasn degradaon
Score 2: moderate 
elasn degradaon
*
c1
*
c4
*
c3
*
c2Collagen
Elasn
Collagen
Elasn
CAA/Aβ
α-SMA
Score 3: severe 
elasn degradaon (focal 
loss of elasn)
CAA/Aβ
α-SMA
Fig. 1  Identification of leptomeningeal arterioles and arteries and 
elastin degradation. Identification of the vessel types shown was 
based on vessel diameters as measured in alpha-smooth muscle actin 
(α-SMA)-stained gyrus frontalis medialis (GFM) and hippocampus 
(HIPP) sections (a). The degradation of the internal elastic lamina 
(b arrow indicates the internal elastic lamina/elastin) was assessed in 
Verhoeff–van Gieson (VVG)-stained small and medium-sized arter-
ies according to the scoring system shown. Elastin degradation due 
to cerebral amyloid angiopathy (CAA) is only observed in the rare, 
not significant number of small and medium-sized arteries with CAA 
fractions >1.0 and in which CAA is present in the media [c, c1: VVG 
stain for elastin (arrow indicates focal loss of elastin) and collagen 
(bright red); asterisk denotes medial layer, arrowhead indicates dou-
ble barrel formation as commonly observed for vessels with severe 
CAA as shown in c2 (image of adjacent section): immunohistochemi-
cal stain for amyloid β (Aβ)/CAA (green) and α-SMA (red)]. Elastin 
appears not to be affected by CAA in small and medium-sized arter-
ies with adventitial CAA burden only [c, c3: VVG stain for elastin 
(arrow indicates preservation of elastin integrity) and collagen; aster-
isk denotes medial layer; c4 (image of adjacent section): immunohis-
tochemical stain for Aβ/CAA and α-SMA]. Scale bar 100 μm
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to 100 µm (arterioles), 100 to 300 µm (small arteries), and 
300 to 700 µm (medium-sized arteries) (Fig. 1a). Veins and 
venules were not imaged and were identified by their rela-
tively small α-SMA-to-lumen ratio. Images were acquired 
using the image acquisition tool of the Visiopharm soft-
ware (Visiopharm, Hørsholm, Denmark). All images were 
acquired in a random manner blinded to subject/Braak 
stage.
Image analysis: measurement of luminal diameter 
and Aβ, collagen, α‑SMA, and neutrophil elastase vessel 
wall ratios
A detailed description of the analysis method can be found 
in the Supplementary Materials and Methods and in Sup-
plementary Fig. 1. The green fluorescent (Aβ) and red fluo-
rescent (α-SMA) image channels were merged in ImageJ 
(National Institutes of Health, Bethesda, ML, USA). 
Stained cells and/or cellular material, e.g. red blood cells 
and collagen deposits, in the lumen of both the merged 
fluorescent and bright field VVG- and neutrophil elastase-
stained vessels were removed using ImageJ to avoid false-
positive measurement hits in the subsequent quantification 
steps. The vessel wall fractions of Aβ (CAA), collagen, 
α-SMA, and neutrophil elastase and the luminal diam-
eters were quantified using an in-house established semi-
automatic quantification script written in MATLAB™ (The 
MathWorks, Inc., Natick, MA, USA).
Image analysis: elastin degradation
The semi-automatic MATLAB™ quantification method 
mentioned above could not consistently detect local, small 
breakages in the arterial elastin layer (Fig. 1b, mild elas-
tin degradation: arrowhead and inset) that were part of the 
elastin degradation process. Therefore, the degree of over-
all arterial elastin degradation was assessed in a semi-quan-
titative, blinded manner (see Supplementary Materials and 
Methods). Since no significant differences in the elastin 
fraction were found between CAA-affected (CAA+) and 
non-CAA-affected (CAA−) arteries—only in rare cases of 
arteries with CAA fractions >1.0 and in which CAA was 
present in the media (Fig. 1c: c2), which were excluded 
from the analysis—and between vessels in the HIPP and 
the GFM, the number of all small arteries and all medium-
sized arteries was pooled per Braak stage.
Statistical analyses
All data were expressed as the mean ± SE and were ana-
lysed using MATLAB™ (The MathWorks, Inc., Natick, 
MA, USA) and GraphPad Prism (GraphPad, Inc., La Jolla, 
CA, USA). CAA+ and CAA− blood vessels were analysed 
separately, except for the analyses shown in Fig. 2a, b. 
Blood vessels of the same type (i.e. arterioles, small arter-
ies, or medium-sized arteries) were pooled per antemortem 
cognitive status of the subjects (AD or NDCTRL), CAA 
fraction, or Braak stage, depending on the analysis. The 
significance of the differences between each vessel type 
and the respective parameter of interest was determined 
using a two-tailed unpaired Student’s t test corrected for 
multiple comparisons (Holm–Sidak test, α = 0.05). Cor-
relations were determined using Spearman’s correlation ρs 
(α = 0.05, CI 95 %, two tailed), except for the analyses of 
Braak pathology vs. arterial elastin degradation for which 
Pearson’s correlation ρp was used (α = 0.05, CI 95 %, two 
tailed) according to a d’Agostino–Pearson omnibus nor-
mality test.
Results
Alpha‑smooth muscle actin is decreased 
in leptomeningeal arterioles and arteries of clinically 
and pathologically defined Alzheimer’s disease subjects
Previous studies have reported that cerebral microves-
sels of subjects with clinically and pathologically defined 
AD exhibited vascular smooth muscle loss and collagen 
increase [54, 55]. To confirm this finding in our study pop-
ulation and to understand whether leptomeningeal arteri-
oles, small arteries, and medium-sized arteries in the same 
subjects might show different pathology, we analysed the 
α-SMA and collagen fraction in the vessel wall of pooled 
(i.e. leptomeningeal CAA+ and CAA−) arterioles, small 
arteries, and medium-sized arteries. We then grouped 
them according to the brain region they surrounded (HIPP 
or GFM) and the clinical, antemortem cognitive status of 
the subjects (AD or NDCTRL) (Fig. 2). All three vessel 
types surrounding the HIPP showed a significant decrease 
in the α-SMA fraction in the AD compared to NDCTRL 
subjects (~30–50 % decrease, p < 0.05) (Fig. 2a, left). 
The α-SMA fraction of the small and of the medium-
sized arteries surrounding the GFM of AD subjects was 
significantly lower than that of their NDCTRL counter-
parts; the α-SMA fraction of arterioles surrounding the 
GFM showed a trend of being lower in the AD subjects 
than in the NDCTRL subjects (Fig. 2a, right). The colla-
gen fractions were not significantly different between the 
AD and NDCTRL subjects in any of the vessel types and 
brain regions (Fig. 2b), although the collagen fraction of 
all three vessel types surrounding the GFM of both the 
AD and NDCTRL subjects tended to be lower than those 
surrounding the HIPP. Thus, overall, leptomeningeal arte-
rioles, small arteries, and medium-sized arteries exhib-
ited significant α-SMA loss in AD subjects whereas their 
742 Acta Neuropathol (2016) 131:737–752
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Fig. 2  Quantification of collagen and alpha smooth muscle actin 
in leptomeningeal arterioles and arteries of Alzheimer’s disease and 
non-demented control subjects. Leptomeningeal vessels surrounding 
the hippocampus (HIPP) of Alzheimer’s disease (AD) subjects show 
a significant decrease in alpha smooth muscle actin (α-SMA) com-
pared to vessels of non-demented control (NDCTRL) subjects (a). 
The α-SMA fraction of small and medium-sized leptomeningeal AD 
arteries surrounding the gyrus frontalis medials (GFM) is also signifi-
cantly decreased; the α-SMA fraction of leptomeningeal AD arteri-
oles surrounding the GFM tends to be decreased (a). The collagen 
fraction of HIPP and GFM AD vessels is not significantly different 
from that of their NDCTRL counterparts (b). Cerebral amyloid angi-
opathy-affected (CAA+) arterioles show exacerbation of the α-SMA 
loss, which is not observed for CAA+ small and medium-sized arter-
ies (c). NDCTRL, AD CAA−, and AD CAA+ vessels have similar 
collagen fractions (c). The graphs represent the mean ± SE of 10 
vessels/vessel category/subject of a total of 45 subjects; *p < 0.05, 
**p < 0.01, and ***p < 0.001 as determined by a two-tailed unpaired 
Student’s t test corrected for multiple comparisons (Holm–Sidak test, 
α = 0.05)
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vessel wall collagen content was similar between the AD 
and NDCTRL subjects.
The van Gieson component of the VVG stain detects 
collagen (bright-red stain) but lacks specificity for the dif-
ferent collagen types, e.g. collagen IV present in the basal 
lamina. Nevertheless, comparison of VVG-stained brain 
sections with adjacent brain sections stained with a mouse 
monoclonal antibody against human collagen IV showed 
similarity in the collagen patterns/distributions within the 
vessel wall between the two staining methods (Supplemen-
tary Fig. 2). The relatively high age of our study population 
may explain the increased collagen IV content in the basal 
lamina/thickening of the basal lamina compared to that in 
young subjects [56]. All VVG-stained vessels were care-
fully isolated from the acquired images and any non-ves-
sel-related collagen was removed from the images to avoid 
quantification of collagen present in the leptomeninges 
and vessel lumen. That the van Gieson component of the 
VVG stain could also detect vessel wall collagen present 
in the medial layer can be appreciated from Supplementary 
Fig. 1, “Collagen fraction”.
Analysis of CAA dependence shows CAA‑dependent 
alpha‑smooth muscle actin loss in leptomeningeal 
arterioles, but not in leptomeningeal arteries
To understand whether the decrease in the α-SMA fraction 
of the arterioles, small arteries, and medium-sized arteries 
in AD subjects (Fig. 2a) was related to CAA pathology and 
if the apparent lack of changes in the collagen fraction was 
due to the pooling of CAA+ and CAA− vessels (dilution 
effect), the three vessel types were analysed according to 
CAA status (CAA+ or CAA−) and antemortem cognitive 
status of the subjects (AD or NDCTRL) (Fig. 2c). None of 
the NDCTRL leptomeningeal vessels showed CAA. The 
α-SMA fraction of both AD CAA+ and CAA− arterioles 
was significantly lower than that of NDCTRL arterioles 
(AD CAA+ arterioles: ~70 % decrease, p < 0.001; AD 
CAA− arterioles: ~40 % decrease, p < 0.01) (Fig. 2c, left). 
Moreover, the α-SMA fraction of AD CAA+ arterioles was 
~50 % lower than that of the AD CAA− arterioles, indi-
cating that CAA exacerbated arteriolar α-SMA loss. Simi-
lar to the findings of Perry et al. [49], the α-SMA fraction 
of AD CAA− and CAA+ small and medium-sized arter-
ies was significantly and equally decreased compared to 
that of NDCTRL small arteries and medium-sized arteries 
(~35–50 % decrease, p < 0.01; Fig. 2c, left), suggestive of a 
CAA-independent decrease in the arterial α-SMA fraction 
in the AD subjects. None of the vessels showed significant 
changes in their collagen fraction (Fig. 2c, right).
To further analyse the CAA-independent decrease in 
the α-SMA fraction of the small- and medium-sized arter-
ies in AD, and to determine whether the apparent effect of 
CAA on the α-SMA fraction of the arterioles in AD cor-
related with the degree of CAA burden, we analysed the 
α-SMA fraction at the different CAA fractions (Fig. 3). 
The vessels were categorised according to their calculated 
vessel CAA fraction. As shown in Fig. 3a, the α-SMA 
fraction was significantly decreased in arterioles with the 
highest CAA fraction/burden (CAA fraction 0.5–1.5 vs. 
0–0.05: 63 % decreased, p < 0.001; CAA fraction 0.5–1.5 
vs. 0.05–0.5: 51 % decreased, p < 0.05), and tended to be 
decreased in arterioles with a CAA fraction between 0.05 
and 0.5 compared to those with a CAA fraction between 
0 and 0.05. A Spearman’s correlation analysis revealed 
that arteriolar CAA burden and α-SMA loss were corre-
lated (CAA and α-SMA: ρs = −0.422, 95 % CI −0.557 
to −0.265, p < 0.0001). In line with the results found for 
small and medium-sized arteries of AD subjects with and 
without CAA (Fig. 2c, “CAA+” and “CAA−”), no signifi-
cant CAA-dependent change in the α-SMA fraction was 
observed in either of these artery types (Fig. 3b). Further 
analysis revealed again that none of the vessels showed 
significant changes in their collagen fraction (Fig. 3, right 
graphs).
Analysis of Braak stage dependence shows 
that leptomeningeal arteries, but not leptomeningeal 
arterioles, exhibit early and Braak stage‑dependent 
alpha‑smooth muscle actin loss
The difference in CAA dependence of α-SMA loss 
between the arterioles and the arteries (Figs. 2, 3), and the 
similarities in collagen content between AD, NDCTRL, 
CAA-, and non-CAA-affected vessels prompted us to 
study whether Braak tau pathology, independent of CAA 
and cognitive status of the subjects, might affect the cer-
ebrovascular α-SMA and collagen content in our study 
population, and whether this might also be vessel type 
dependent. To this end, the α-SMA and collagen frac-
tions of arterioles, small arteries, and medium-sized arter-
ies without CAA (“CAA−”) were categorised according 
to Braak stage, rather than to antemortem clinical AD or 
NDCTRL diagnosis (Fig. 4). A significant decrease in the 
α-SMA fraction was observed for small and medium-sized 
arteries between Braak stage I and II–III (small arteries: 
~25 % decrease, p < 0.05; medium-sized arteries: ~50 % 
decrease, p < 0.01). Although the α-SMA fraction of both 
artery types was not significantly different between Braak 
stage II and VI (Fig. 4a), comparison of the α-SMA frac-
tion between Braak stage I and IV, I and V, and I and VI 
showed a further significant decrease in the α-SMA frac-
tion of both artery types (p < 0.01–0.001). Separate correla-
tion analysis considering all Braak stages and the respec-
tive α-SMA fraction showed that these two parameters 
were weakly correlated in the small arteries and moderately 
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correlated in the medium-sized arteries (ρs small arter-
ies = −0.216, 95 % CI −0.317 to −0.110, p < 0.001; ρs 
medium-sized arteries = −0.433, 95 % CI −0.640 to 
−0.167, p < 0.001). Similar to what was found by others 
[54], arteriolar α-SMA loss was not Braak stage depend-
ent, and a significant decrease in the arteriolar α-SMA frac-
tion was observed only at Braak stage V and VI (~40–45 % 
decrease, p < 0.05–0.01) (Fig. 4a).
The collagen fraction of small arteries of Braak stage 
II–III and VI subjects was significantly decreased com-
pared to that of their Braak stage I counterparts (Braak 
stage II–III: ~21 % decrease, p < 0.05; Braak stage VI: 
~43 % decrease, p < 0.01) (Fig. 4b); Braak stage and the 
observed decreased collagen fraction of the small arter-
ies were, however, only weakly correlated (ρs = −0.256, 
95 % CI −0.390 to −0.112, p < 0.001). Although not sig-
nificant, medium-sized arteries tended to show an increase 
in the collagen fraction between Braak stage I and II–III 
and I and VI (~25 % increase, p = 0.07 and p = 0.09) 
(Fig. 4b). Similar to the lack of Braak stage-dependent 
arteriolar α-SMA loss, the arterioles in these CAA-nega-
tive samples did not show a significant change or trend in 
the collagen fraction with increasing Braak stage (Fig. 4b), 
further confirming the Braak tau-independent origins of 
the microvascular pathology found in this and a previous 
study [54].
Fig. 3  Relationship between 
cerebral amyloid angiopathy 
burden and the collagen and 
alpha-smooth muscle actin frac-
tion of leptomeningeal arterioles 
and arteries. Leptomeningeal 
arterioles with the highest cere-
bral amyloid angiopathy (CAA) 
burden (“CAA fraction”) 
surrounding the gyrus frontalis 
medialis (GFM) and hippocam-
pus (HIPP) show a significant 
decrease in the alpha-smooth 
muscle actin (α-SMA) fraction 
(a), whereas CAA burden does 
not affect these fractions in the 
leptomeningeal small arteries 
(b) and medium-sized arteries 
(c). None of the vessels show 
an effect of CAA burden on 
the collagen fraction (a–c). 
Mean ± SE of ~30–70 vessels/
vessel category; **p < 0.01 and 
***p < 0.001 as determined by 
a two-tailed unpaired Student’s 
t test corrected for multiple 
comparisons (Holm–Sidak test, 
α = 0.05)
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Braak tau pathology does not significantly affect 
the wall‑to‑lumen ratio and the luminal diameter 
of leptomeningeal vessels
As described by others, CAA-affected vessels show a 
decrease in their wall-to-lumen ratio [29, 54]. Contrary 
to this, herein, we found that Braak tau pathology did not 
significantly alter the wall-to-lumen ratio of the arteri-
oles, small arteries, and medium-sized arteries at all Braak 
stages analysed (Supplementary Fig. 3a). The average wall-
to-lumen ratio at all Braak stages of the arterioles, small 
arteries, and medium-sized arteries was 0.37, 0.29, and 
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Fig. 4  Relationship between Braak pathology, the collagen and 
alpha-smooth muscle actin fraction of leptomeningeal arterioles and 
arteries, and perivascular accumulation of phosphorylated paired 
helical filament tau. Small and medium-sized leptomeningeal arter-
ies surrounding the gyrus frontalis medialis (GFM) and hippocam-
pus (HIPP) show a significant reduction in the alpha-smooth mus-
cle actin (α-SMA) fraction between Braak stage I and II–III, which 
remains reduced throughout the later Braak stages; leptomeningeal 
arterioles show a significant α-SMA loss only at Braak stage V and 
VI (a). The collagen fraction of only small arteries is significantly 
changed (i.e. reduced) with increasing Braak stage (b). Mean ± SE of 
10 vessels/vessel category/subject of a total of 45 subjects; *p < 0.05, 
**p < 0.01, and ***p < 0.001 as determined by a two-tailed unpaired 
Student’s t test corrected for multiple comparisons (Holm–Sidak test, 
α = 0.05). Intraparenchymal perivascular accumulation of phospho-
rylated paired helical filament tau (PHF-tau) (c upper panel PHF-tau 
staining: area indicated by arrowheads is shown enlarged in inset; 
asterisks indicate intraneuronal PHF-tau) is accompanied by α-SMA 
loss (c upper panel α-SMA staining: arrowheads point to discontin-
uous α-SMA staining; enlarged in inset). Compare with the largely 
continuous, uniform α-SMA staining of a small intraparenchymal 
artery without perivascular PHF-tau accumulation (c lower two pan-
els; PHF-tau staining: arrowhead points to absence of perivascular 
PHF-tau; area indicated by arrowhead is shown enlarged in inset; 
asterisks indicate intraneuronal PHF-tau). The proportion of subjects 
per Braak stage with parenchymal perivascular PHF-tau accumula-
tion is increased with increasing Braak tau pathology (d). All images 
were acquired from consecutive HIPP sections of a Braak stage II 
subject. Scale bar 50 μm
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0.25, respectively, in line with the reduction in this ratio 
with increasing vessel size [4]. The relatively high values 
found for all three vessel types may be expected for ves-
sels from aged subjects [2, 56]. The lack of a change in 
the arteriolar wall-to-lumen ratio with increasing Braak 
stage agrees with previous findings [54] and with our other 
results of Braak stage-independent changes in the arterioles 
described herein. We ascribe the unchanged wall-to-lumen 
ratio of the small and medium-sized arteries to the fact 
that we measured the overall, total thickness of the vessel 
wall (intima to outer layer of the adventitia) to correct for 
the arterial Braak stage-dependent α-SMA loss described 
above, which would otherwise skew these results. Thus, 
arterial α-SMA loss did not affect the overall, total vessel 
wall thickness of the arteries.
Analysis of the luminal diameter per Braak stage, how-
ever, revealed that the percentage of arterioles within the 
smallest luminal diameter range measured (50–75 µm) was 
increased at Braak stage V and VI (~20–25 % increase) 
although this was not significant (p > 0.05) (Supplementary 
Fig. 3b). A less pronounced shift toward decreased lumi-
nal diameters was observed for small arteries (Braak stage 
IV and higher) and medium-sized arteries (Braak stage II/
III and higher) (Supplementary Fig. 3b). Given the rela-
tively high α-SMA but low collagen content of specifically 
arterioles—i.e. low arteriolar wall stiffness—compared to 
arteries, arteriolar loss of α-SMA-positive cells/vascular 
smooth muscle cells as we found at Braak stage V and VI 
(Fig. 4) may explain the more profound decrease in arteri-
olar luminal diameter compared to that of the stiffer small 
and medium-sized arteries. These reductions in arteriolar 
luminal diameter may play a role in cerebral hypoperfusion 
at progressive Braak tau stages as found in previous stud-
ies [3, 9, 41]. On the other hand, the lack of a profound 
effect of Braak stage on luminal diameter of the leptome-
ningeal arteries, which are upstream of the arterioles, sug-
gests that cerebral hypoperfusion—at least at early Braak 
tau stages—may be more related to altered arterial wall 
compliance causing alterations in perivascular drainage and 
blood flow regulation rather than to actual arterial luminal 
diameter changes.
Accumulation of phosphorylated paired helical filament 
tau in the perivascular space of intraparenchymal 
vessels is accompanied by intraparenchymal 
alpha‑smooth muscle actin loss and increases 
with Braak stage
Given that accumulation of PHF-tau has been observed in 
the perivascular space of both CAA-affected and -unaf-
fected intraparenchymal vessels in subjects with sporadic 
AD [48, 57], we hypothesised that the CAA-independent 
but Braak stage-dependent loss of α-SMA in the small 
and medium-sized leptomeningeal arteries (Figs. 3b, c, 
4a) might have been related to the perivascular drainage 
of toxic PHF-tau species from intraparenchymal vessels to 
the leptomeningeal arteries. Staining of HIPP sections of 
all 45 subjects for PHF-tau revealed the presence of PHF-
tau in the perivascular space of intraparenchymal vessels in 
especially the CA1 region bordering the subiculum [33] in 
subjects with Braak stage II pathology and higher (Fig. 4c, 
Supplementary Fig. 4). The number of subjects affected by 
PHF-tau increased with progression of Braak tau pathology 
(Fig. 4d); however, the number of vessels showing this phe-
nomenon highly varied between the subjects (on average, 
5–20 vessels out of 50 vessels analysed were affected in the 
subjects). Perivascular PHF-tau accumulation was observed 
around intraparenchymal veins, arterioles, and small arter-
ies, and was accompanied by α-SMA loss (Fig. 4c, Sup-
plementary Fig. 4). None of the leptomeningeal vessels 
analysed in this study showed such perivascular PHF-tau 
accumulation, indicating that potential PHF-tau-related 
α-SMA loss in the leptomeningeal arteries might only have 
been caused by perivascular drainage of soluble PHF-tau 
species.
Leptomeningeal arteries exhibit Braak stage‑dependent 
elastin degradation starting at early Braak tau 
pathology
The arterial internal elastic lamina is formed by vascu-
lar smooth muscle-derived elastin and plays an impor-
tant role in vessel wall distension and recoil at normally 
elevated blood pressure levels [44, 58]. Elastin can be 
degraded enzymatically, chiefly by neutrophil- and/or vas-
cular smooth muscle-derived neutrophil elastase, and by 
chronic hypertensive vessel wall stress [31, 34, 42, 43]. 
Importantly, vessel wall collagen governs vessel wall dis-
tension during high-pressure vessel wall stress [44, 58]. 
Given the significant Braak stage-dependent α-SMA loss 
in both the small and medium-sized arteries and collagen 
loss in the small arteries (Fig. 4), we hypothesised that 
arterial elastin might also be affected by Braak tau pathol-
ogy. Indeed, quantification of arterial elastin degradation 
revealed a Braak stage-dependent increase in the percent-
age of small arteries with moderate elastin degradation 
(score 2, 26 % increase) between Braak stage II and VI, 
which was accompanied by a decrease in the percentage 
of small arteries without (score 0, 42 % decrease) and with 
mild (score 1, 32 % decrease) elastin degradation (Fig. 5a, 
left). However, between Braak stage I and II, the percent-
age of small arteries in all three elastin degradation cate-
gories was decreased, which was reflected by an increase 
in the percentage of vessels without elastin degradation 
(score 0, ~40 % increase). The percentage of small arter-
ies with severe elastin degradation was sharply increased 
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between Braak stage II and III (score 3, 33 % increase), 
and largely remained at this level at the later Braak stages. 
The elastin degradation in the medium-sized arteries was 
less severe than that observed in the small arteries, and fol-
lowed a different pattern (Fig. 5a, right). The percentage 
of medium-sized arteries with mild and moderate elastin 
degradation was increased between Braak stage II and IV 
(score 1, 33 % increase; score 2, 16 % increase). However, 
the percentage of medium-sized arteries with mild elastin 
degradation was sharply decreased between Braak stage 
IV and VI (score 1, 26 % decrease), and this was accom-
panied by an increase in the medium-sized arteries without 
elastin degradation (score 0, 33 % increase) (Fig. 5a). The 
percentage of medium-sized arteries with moderate elastin 
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Fig. 5  Quantification of Braak stage-dependent elastin degradation 
and neutrophil elastase presence in the wall of leptomeningeal arter-
ies. Elastin in leptomeningeal arteries is degraded in a Braak stage-
dependent manner, which differs between small and medium-sized 
leptomeningeal arteries (a). The percentage of small arteries with 
moderate (score 2) elastin degradation is increased between Braak 
stage II and VI; the percentage of small arteries with severe elastin 
degradation sharply increases between Braak stage II and III and 
remains at this level between Braak stage III and VI (a left). The per-
centage of medium-sized leptomeningeal arteries with moderate elas-
tin degradation (score 2) is increased between Braak stage II and III 
and remains at this level between Braak stage III and VI (a right). 
The overall percentage of medium-sized arteries with severe elastin 
degradation is not increased between Braak stage I and VI (a). Severe 
arterial elastin degradation [b Verhoeff–van Gieson (VVG) stain: 
arrow in inset indicates focal elastin loss] tends to be accompanied 
by increased vessel wall neutrophil elastase fractions (b Ntrelast: 
arrow; c bar graph). Confocal microscopy of Ntrelast in the arterial 
wall reveals Ntrelast expression by α-SMA-positive cells/smooth 
muscle cells [d right panel co-localisation (yellow) and arrows]. 
Ntrelast-positive cells attached to the luminal side of the intimal layer 
(d arrowheads and asterisk) and present between the leptomenin-
geal layer and the adventitia (d number sign) are identified as neu-
trophils (Ntrelast is also a neutrophil-specific marker), and are not 
α-SMA-positive cells [d middle panel absence of α-SMA staining 
around DAPI-stained nuclei at the luminal side of the intimal layer 
(arrowheads and asterisk) and between the leptomeningeal layer and 
the adventitia (number sign)]. Some neutrophils have a flattened mor-
phology (d left and right panel: arrowheads), suggestive of diapede-
sis. Scale bar 20 μm
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degradation, however, remained largely stable between 
Braak stage III and VI (score 2, 25 and 23 %, respec-
tively) (Fig. 5a). The percentage of medium-sized arteries 
with severe elastin degradation was not changed consider-
ably between all Braak stages analysed (score 3, ~6–9 %), 
except at Braak stage III (score 3, 19 %) and V (score 3, 
13 %) (Fig. 5a). CAA appeared to affect elastin integrity 
only in the rare number of small and medium-sized arter-
ies affected heavily by CAA in which CAA was present 
in the media (Fig. 1c: c1 and c2), but not in the small and 
medium-sized arteries with adventitial CAA burden only 
(Fig. 1c: c3 and c4).
As shown in Table 2, correlation analysis revealed a 
significant positive correlation between Braak stage and 
moderate elastin degradation in the small arteries. How-
ever, no significant correlation between Braak stage and 
any of the four elastin degradation categories was observed 
in the medium-sized arteries. These and the above results 
showed that elastin degradation in small arteries progressed 
with Braak tau pathology, whereas elastin degradation in 
medium-sized arteries was less prevalent and, although it 
progressed between Braak stage II and III, it did not further 
increase in severity during the more advanced Braak stages.
We postulate that the significant collagen loss with pro-
gressing Braak stage pathology specifically in the small 
arteries causes higher vessel wall stress and thus more 
pressure-induced elastin loss in these vessels than in the 
medium-sized arteries. This may explain the difference in 
elastin degradation severity between these otherwise simi-
lar artery types.
Severe leptomeningeal arterial elastin degradation 
tends to be accompanied by increased leptomeningeal 
arterial smooth muscle neutrophil elastase expression
The enzymatic degradation of elastin referred to above 
is prominent in chronic obstructive pulmonary disease 
(COPD), where neutrophil-derived neutrophil elastase 
compromises the vessel wall integrity of pulmonary arter-
ies resulting in emphysema [31]. Inhibition of neutrophil 
elastase alleviates elastin degradation and emphysema in 
COPD [1, 31], as well as vasogenic edema and neuronal 
loss in acute cerebral ischemia and traumatic brain injury 
[28, 53]. Here, severe elastin degradation in small and 
medium-sized arteries (Fig. 5b) tended to be accompa-
nied by increased vessel wall neutrophil elastase fractions 
(Fig. 5b, c). Confocal microscopy revealed that the neutro-
phil elastase observed within the vessel wall was expressed 
by α-SMA-positive cells/smooth muscle cells (Fig. 5d, 
arrows in right panel) and most likely not by neutrophils 
(neutrophil elastase is also a specific neutrophil marker) 
as these were only observed attached to the luminal side 
of the intimal layer (Fig. 5d, asterisk and arrowheads) 
and between the leptomeningeal layer and the adventitia 
(Fig. 5d, number sign). However, extravasation of neutro-
phils into the vessel wall could not be ruled out, as some 
neutrophils attached to the luminal side of the intimal layer 
exhibited a flattened morphology suggestive of diapedesis 
(Fig. 5d, arrowheads). Thus, these results suggest a role for 
increased and/or aberrant neutrophil elastase expression by 
smooth muscle cells in severe elastin degradation in lep-
tomeningeal arteries.
Discussion
Herein, we found that leptomeningeal arteries show CAA-
independent pathologic vessel wall remodelling that is 
related to early Braak tau pathology, while leptomenin-
geal arterioles only show significant vessel wall remodel-
ling at late/AD Braak stages and which is CAA dependent. 
This suggests that early, pre-AD cerebral artery pathology 
unrelated to Aβ burden may contribute to the impairment 
of downstream arterioles in AD. Nonetheless, the follow-
ing two major limitations of our study need to be consid-
ered: the relatively small population size and the exclusion 
Table 2  Correlation analysis 
between the number of 
small and medium-sized 
leptomeningeal arteries in the 
respective elastin degradation 
category and Braak stage
“0”, “1”, “2”, and “3” = no, mild, moderate, and severe elastin degradation, respectively
CI confidence interval
* Significant
a Braak stages included: I–VI
b Pearson’s correlation (α = 0.05, two tailed)
Small arteries Medium-sized arteries
ρp
b CI (95 %) p ρp
b CI (95 %) p
Braaka vs. “0” −0.707 −0.965 to 0.246 0.116 −0.546 −0.941 to 0.476 0.262
Braaka vs. “1” −0.955 −0.995 to −0.638 0.003* 0.489 −0.535 to 0.931 0.325
Braaka vs. “2” 0.909 0.370 to 0.990 0.012* 0.706 −0.247 to 0.965 0.117
Braaka vs. “3” 0.792 −0.056 to 0.976 0.061 −0.041 −0.825 to 0.797 0.939
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of intraparenchymal vessels in the majority of our analy-
ses. (1) Although our population size and Braak stage 
range were similar to those of previous studies [17, 54, 
55], the majority of subjects had vascular-related morbidi-
ties, including chronic hypertension, diabetes type 2, and 
cardiac impairment. These factors were not biased toward a 
specific Braak stage (Table 1) but all of them could impact 
vascular health. (2) Our goal was to determine the effects 
of Braak tau pathology and CAA on the cerebrovascula-
ture. Therefore, to avoid measuring these along with the 
(combined) effects of parenchymal Aβ plaques, neurofibril-
lary tangles, glial cells, and the accompanying pathologic 
changes in the parenchymal brain milieu on vessel wall 
remodelling, we had analysed only leptomeningeal vessels. 
Consequently, potential Braak stage- and CAA-dependent 
pathology of intraparenchymal vessels, except for perivas-
cular PHF-tau accumulation, was not determined.
Our findings of Braak stage-dependent arterial elastin 
degradation offer insight into an understudied pathology of 
the cerebral arteries. Elastin loss is known to contribute to 
vessel tortuosity and, thereby, aberrant perfusion [34, 47]. 
Thus, the arterial elastin degradation we have observed 
may play a role in previously described impaired perivas-
cular drainage [25–27, 59, 62] and cerebral hypoperfusion 
that worsens with advancing Braak stages [3, 9, 41]. Espe-
cially, reduced brain tissue oxygenation due to cerebral 
hypoperfusion becomes significant at Braak stage III–IV 
[41], similar to the moderate and severe arterial elastin 
degradation we found. Such arterial elastin degradation 
is, to our knowledge, not known to be present in relatively 
healthy aged individuals [19]. Given that the majority of 
the Braak stage IV and all of the Braak stage V and VI sub-
jects had clinically and pathologically defined AD and that 
moderate and severe elastin degradation were prominent at 
these advanced Braak stages, elastin degradation might be 
an important degenerative process contributing to vessel 
wall pathology affecting vascular tone in AD. The trend for 
an increased expression of neutrophil elastase by α-SMA-
positive cells in the arteries with severe elastin degradation 
we found points to one potential mechanism underlying 
the observed arterial elastin degradation, which we are cur-
rently studying in detail. Other potential mechanisms are 
(1) the upregulated expression and/or activity of matrix 
metalloproteinases (MMPs), particularly MMP-2 and 
MMP-9, in the vessel wall as they are known to degrade 
arterial elastin, are linked to mild cognitive impairment and 
AD, and are activated by Aβ oligomers [10, 24, 35]; and 
(2) altered production of vascular smooth muscle-derived 
arterial elastin due to the change of a contractile to a prolif-
erative vascular smooth muscle phenotype [30, 47]. In light 
of the latter, elastin is known to promote the physiological 
contractile, non-proliferative vascular smooth muscle phe-
notype [30, 47]; thus, elastin loss/degradation in itself may 
contribute to changes in vascular smooth muscle behaviour. 
Important to note here is that neutrophil elastase induces 
both vascular smooth muscle cell apoptosis and increased 
vascular smooth muscle expression of pro-inflammatory 
chemokines causing vessel wall remodelling [12, 46]. 
These findings suggest that the loss of arterial α-SMA-
positive cells/smooth muscle cells we describe may 
also be related to the cells’ increased neutrophil elastase 
expression.
The CAA-independent but Braak stage-dependent 
α-SMA loss in both artery types from Braak stage II/
III onward we observed was supported by previous find-
ings of CAA-independent vascular smooth muscle loss in 
the posterior cerebral artery in AD [49], and was different 
from the CAA dependence of the arteriolar/microvascular 
α-SMA loss we and others [17, 54, 55] had found. CAA 
causes pathologic remodelling of the vessel wall that is 
linked to CAA-induced hypoperfusion [11] and impaired 
perivascular drainage [26]. Conversely, chronic, CAA-/
Aβ-independent hypoperfusion instigates microvascular 
CAA formation, cortical microinfarcts, and neurovascu-
lar dysfunction [16, 45], and progresses with Braak tau 
pathology [9, 41]. Further, while Aβ42-induced endothe-
lin-1 upregulation causing vasoconstriction/hypoperfu-
sion becomes significant only at Braak stage V–VI/in AD 
patients [41], as mentioned, significantly reduced cerebral 
tissue oxygenation can already be observed at Braak stage 
III–IV [41]. The finding of PHF-tau accumulation in the 
perivascular space of intraparenchymal vessels starting at 
early Braak stages we describe here and is present in AD 
as has been reported by others [48, 57] may suggest a tau 
pathology-driven mechanism underlying this hypoperfu-
sion. Given that the intraparenchymal vessels with perivas-
cular PHF-tau accumulation showed α-SMA loss, and that 
perivascular molecules have access to perivascular drainage 
pathways and thus leptomeningeal arteries [26, 60, 62], it is 
likely that toxic (oligomeric) PHF-tau species contributed 
to the early Braak stage arterial α-SMA loss. This notion is 
supported by the fact that arterial α-SMA loss, arterial elas-
tin degradation, and intraparenchymal perivascular PHF-
tau accumulation all started around Braak stage II–III, sug-
gesting a link between the loss of vessel wall constituents 
important for cerebral blood flow/perivascular drainage and 
perivascular PHF-tau.
Yet, a potential involvement of Aβ in the early arterial 
wall changes observed herein cannot be ruled out. Soluble 
Aβ oligomeric species, for example, are already present at 
Braak stage I–II [37]. Even though Aβ oligomer-mediated 
vasoconstriction via endothelin-1 upregulation may be 
unlikely to occur at early, pre-AD Braak stages as men-
tioned above, (soluble) Aβ oligomers are cytotoxic and 
can be generated by vascular smooth muscle cells [20, 21]. 
Neuron-derived Aβ oligomers, similar to tau oligomers, 
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are cleared along and may accumulate around the leptome-
ningeal arteries through the workings of the perivascular 
drainage system [26, 60]. Furthermore, although a clear 
effect of CAA on arterial elastin was not observed in this 
study, amyloidogenic proteins have been reported to bind 
and interact with elastin [18, 63] and, as mentioned, can 
activate MMPs, which degrade elastin.
We propose a disease model in which the loss of arterial 
vascular smooth muscle and degradation of arterial elastin 
are related to early Braak tau pathology (“Arterial Pathol-
ogy Stage”) (Fig. 6). This arterial remodelling impairs 
the arterial wall distension dynamics that drive perivas-
cular clearance and decreases the arteries’ aortic blood 
propulsion wave cushioning capacity, which increases 
the distension and shear stress on the downstream, rela-
tively fragile arteriolar and capillary walls [51]. With time, 
this microvessel wall stress leads to pathologic arteriolar 
and capillary remodelling and, ultimately, contributes to 
CAA- and AD-related microvascular pathology (Fig. 6, 
“Microvascular Pathology Stage”). Thus, a combination 
of vessel-specific therapeutics that protect and improve 
cerebral vessel wall dynamics and, hence, cerebral perfu-
sion/clearance, and therapeutics directed against neuronal 
or aggregated protein targets may hold more promise than 
AD monotherapy.
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Fig. 6  Proposed model of early Braak stage, tau pathology-depend-
ent remodelling of cerebral arteries instigating cerebral amyloid angi-
opathy-related microvascular pathology. In the vascular system under 
healthy, physiological conditions (a), arteries cushion the blood pro-
pulsion wave amplitudes originating from aortic blood propulsions 
by distension of their vessel wall. This mechanism ensures that the 
blood propulsion wave amplitudes are decreased such that the ones 
experienced by the downstream, relatively fragile arterioles and capil-
laries are proportional to their small vessel wall distension capacity. 
Arterial elastin degradation and vascular smooth muscle loss start at 
early Braak tau stages (b), coincide with increasing (perivascular) tau 
pathology, and reduce the arterial wall distension, compliance, and 
overall arterial blood flow-regulating capacity. Consequently, arterial 
cushioning of aortic blood propulsion waves is diminished, increasing 
the distension and shear stress experienced by the arterioles and cap-
illaries. With time, this pathologic, artery-driven mechanism contrib-
utes to remodelling of cerebral microvessels and the development of 
cerebral amyloid angiopathy (CAA)-related microvascular pathology 
characteristic in Alzheimer’s disease (AD)
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